Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001091872 | SCV001248132 | uncertain significance | not provided | 2019-11-01 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002497494 | SCV002814875 | uncertain significance | Polycystic kidney disease, adult type | 2022-05-17 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003973049 | SCV004786654 | uncertain significance | PKD1-related disorder | 2023-10-31 | no assertion criteria provided | clinical testing | The PKD1 c.9631G>A variant is predicted to result in the amino acid substitution p.Ala3211Thr. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0055% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/16-2150248-C-T). The p.Ala3211 residue is weakly conserved during evolution and at this position is a threonine (Thr) in rat and mouse. Although we suspect this variant could be benign, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |